AFTD stands for the Association for Frontotemporal Degeneration, the leading organization dedicated to a brain disease called frontotemporal degeneration, or FTD. FTD is not a single disease but a family of neurodegenerative conditions that damage neurons in the frontal and temporal lobes of the brain. These are the areas responsible for personality, behavior, decision-making, and language. It typically strikes earlier than Alzheimer’s, often in a person’s 50s or early 60s, and it progresses over the course of several years.
How FTD Differs From Alzheimer’s
While Alzheimer’s disease is best known for erasing memory, FTD primarily changes who a person seems to be. The frontal lobes govern impulse control, social behavior, motivation, and planning. The temporal lobes handle language comprehension and emotional processing. When neurons in these regions die, the earliest signs are usually personality shifts or trouble with speech, not forgetfulness. This distinction is one reason FTD is so often missed or misdiagnosed early on.
FTD also tends to appear at a younger age. Studies across multiple countries place the average onset between the mid-50s and mid-60s, with roughly 13% of cases beginning before age 50. That makes it one of the most common causes of dementia in people under 65.
The Three Main Types
FTD is typically grouped into three broad categories based on which symptoms appear first.
Behavioral variant FTD (bvFTD) is the most common form. Its hallmark is a change in personality: a previously considerate person may become impulsive, say inappropriate things, or lose interest in relationships and responsibilities. Other common features include emotional flatness, loss of empathy, compulsive behaviors, and changes in eating patterns (often a new craving for sweets or carbohydrates). Apathy and social withdrawal can be just as prominent as disinhibition.
Primary progressive aphasia (PPA) affects language rather than behavior. It comes in two main forms. In one, called semantic dementia, a person gradually loses the meaning of words. They can still speak fluently, but their vocabulary shrinks and they struggle to understand what others are saying. In the other form, called progressive nonfluent aphasia, speech itself becomes effortful and halting. Grammar breaks down, and forming sentences takes visible concentration. Behavioral changes may develop later in the disease course, but language trouble comes first.
Movement-related variants overlap with conditions like ALS (amyotrophic lateral sclerosis) and other motor disorders. Some people with bvFTD also develop muscle weakness and wasting characteristic of motor neuron disease. Others experience stiffness, slowness, tremor, or difficulty with balance and eye movements. These overlapping syndromes reflect the fact that the same underlying brain pathology can affect different neural circuits in different people.
What Happens in the Brain
At a biological level, FTD involves abnormal clumps of protein building up inside brain cells and eventually killing them. About 40% of cases involve a protein called tau, which normally helps stabilize the internal structure of neurons. In these cases, tau becomes misfolded and accumulates in toxic clusters. People with tau-based FTD tend to have a somewhat slower disease course, with a median survival of around 9 years from symptom onset.
In most of the remaining cases, the culprit is a different protein called TDP-43. This form is associated with faster progression, a median survival closer to 5 years, and a higher likelihood of developing motor neuron symptoms alongside cognitive or behavioral changes. A smaller number of cases involve a third protein, FUS, while a handful remain unclassified. There is currently no way to determine which protein is involved during a person’s lifetime without specialized testing, though researchers are working on it.
Genetics and Family History
FTD has a stronger genetic component than many other dementias. About 15% of familial cases are caused by inherited mutations in one of three genes. Mutations in the MAPT gene lead to tau-based disease. Mutations in the GRN gene and a specific repeat expansion in a gene called C9ORF72 are linked to TDP-43 pathology. The C9ORF72 expansion is particularly notable because it can cause both FTD and ALS, sometimes in the same person or within the same family.
Having a parent or sibling with FTD increases risk, but the majority of cases occur without a clear family pattern. Genetic counseling can help families with multiple affected members understand their situation.
Why It’s So Often Misdiagnosed
One of the most frustrating aspects of FTD is how long it takes to get the right diagnosis. Studies consistently show an average delay of about 4 to 4.5 years between the first symptoms and a confirmed diagnosis. In one study of behavioral variant FTD, more than 70% of patients were initially given a psychiatric diagnosis instead. Women were most commonly told they had depression or bipolar disorder, while men were frequently diagnosed with anxiety or a psychotic disorder.
This happens because the early symptoms of bvFTD, things like apathy, impulsiveness, emotional detachment, or erratic behavior, look a great deal like psychiatric illness. The person is often relatively young and physically healthy, which makes a degenerative brain disease seem unlikely. Many patients cycle through psychiatric treatments for years before a neurologist identifies the true cause. Brain imaging, which can reveal shrinkage in the frontal or temporal lobes, plays a key role in eventually reaching the correct diagnosis.
Treatment and Day-to-Day Management
There is currently no treatment that slows or stops FTD. Medications used for Alzheimer’s disease are not effective here, and drugs prescribed for behavioral symptoms have shown limited benefit with significant side effects. As a result, non-drug strategies form the backbone of FTD care.
These approaches focus on adapting the person’s environment and routines to reduce distress and manage difficult behaviors. Occupational therapists can identify a person’s remaining strengths and restructure daily activities accordingly. Reintroducing familiar hobbies and games has been shown to reduce disinhibition and inappropriate behaviors. Structured activities tend to work better than unstructured free time, and music appears to be particularly helpful. For compulsive behaviors, simple substitutions can make a real difference: offering a squeeze ball to someone who compulsively touches others, or a lollipop to reduce repetitive vocalizations.
Caregiver training is equally important. Learning to recognize triggers for agitation, simplifying communication, and restructuring the home environment can improve quality of life for everyone involved. A meta-analysis of combined patient-caregiver interventions found benefits comparable to antipsychotic medications, without the associated risks.
Life Expectancy
Survival varies significantly depending on the subtype. For the behavioral variant, median survival from symptom onset is roughly 6 years. When FTD occurs alongside motor neuron disease, the timeline is shorter, closer to 3 years. Cases driven by tau pathology tend to progress more slowly, with median survival around 9 years, compared to about 5 years for non-tau forms. These are median figures, meaning individual experiences vary widely in both directions.
The Role of the AFTD Organization
The Association for Frontotemporal Degeneration (AFTD) is the primary U.S.-based nonprofit dedicated to FTD research, education, and support. Their HelpLine (866-507-7222), staffed by social workers, offers guidance on navigating a new diagnosis, understanding subtypes, and connecting with local resources. AFTD provides diagnostic checklists for healthcare providers, printable cards that explain FTD-related behavior to bystanders in public settings, and sample letters that families can give to doctors, lawyers, or law enforcement to explain the condition. They also offer modest financial grants through their Comstock Grant program to help people with FTD and their caregivers maintain quality of life, including funding for travel to AFTD education conferences.